Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line
Brief Summary: Bevacizumab has been found to prolong progression free survival in first line, and more recently, in second line treatment for platinum sensitive ovarian cancer patients who had not received prior treatment with bevacizumab.

Recently reported data suggest that patients with colon cancer who receive bevacizumab in more than one line of therapy (beyond progression) have better results. In ovarian cancer, the role of bevacizumab administered in both first and second-line therapies needs to be defined.

This study aims to evaluate whether administering bevacizumab in combination with chemotherapy in second-line therapy to patients with recurrent ovarian cancer who have received first-line bevacizumab will be more effective than chemotherapy alone.


Options:
A: Arm Label: chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin, Drug: pegylated liposomal doxorubicin, Drug: Gemcitabine | Arm Label: Chemotherapy and bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Paclitaxel, Drug: Carboplatin, Drug: pegylated liposomal doxorubicin, Drug: Gemcitabine | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy and bevacizumab | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Chemotherapy and bevacizumab, chemotherapy
B: Arm Label: 1 non-continuous; Type: OTHER; Interventions: Drug: Sunitinib | Arm Label: 2 continuous; Type: OTHER; Interventions: Drug: SUNITINIB | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): 1 non-continuous | Intervention Type: DRUG; Name: SUNITINIB; Assigned to Arm(s): 2 continuous
C: Arm Label: Placebo plus PLD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus PLD | Arm Label: AMG386 plus PLD; Type: EXPERIMENTAL; Interventions: Drug: AMG386 plus PLD | Intervention Type: DRUG; Name: AMG386 plus PLD; Assigned to Arm(s): AMG386 plus PLD | Intervention Type: DRUG; Name: Placebo plus PLD; Assigned to Arm(s): Placebo plus PLD
D: Arm Label: Olaratumab and Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Arm Label: Liposomal Doxorubicin: Optional Olaratumab Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Intervention Type: BIOLOGICAL; Name: Olaratumab; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin

Answer: A